- Healthcare 150
- Posts
- Healthcare PE Gets More Selective: Where Capital Is Concentrating
Healthcare PE Gets More Selective: Where Capital Is Concentrating
Behavioral health, biosensors and biotech are attracting capital—but execution is becoming the real differentiator.
Gaston Brizuela Bosio
August 18, 2026
Good morning, ! It’s Friday, and healthcare investing is entering a more selective phase. Capital is concentrating around businesses that can execute—not just innovate—from behavioral health consolidation to biosensors becoming part of the healthcare data stack. Meanwhile, biotech funding is returning, but investors are demanding more validation and clearer paths to commercialization.
Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.
Join PE150 and Caplink for our AI & Data Insight Breakfast in London. Register here.
DATA DIVE
Healthcare Capital Is Moving From Innovation to Execution
Healthcare investors are becoming more selective, and the report’s data shows where conviction is concentrating. 50% of respondents expect behavioral health to lead healthcare services consolidation over the next 24 months, versus 33% for physician practice management and 17% for home based care. Fragmentation and persistent capacity constraints make behavioral health particularly suited to platform building.
The same preference for execution is visible in digital health. 39% identify health system complexity as the biggest barrier to enterprise scale, while 31% cite unclear clinical ROI and 30% weak reimbursement. Meanwhile, 54% believe Clinical Decision Support could produce the next $10B digital health company.
Capital allocation is already reflecting that shift. Digital health startups raised $4B across 110 transactions in Q1 2026, but just 12 megadeals captured 59% of funding.
For investors, the implication is increasingly clear. Scale itself is becoming a moat. The premium is moving toward businesses that can consolidate fragmented markets or become embedded in clinical workflows, not simply introduce another technology layer. (Click HERE for the full report)
HEALTHTECH CORNER
Biosensors Are Becoming Healthcare Infrastructure
The global biosensors market is projected to expand from $27B in 2022 to $63B by 2032, more than doubling in a decade. More importantly, the chart shows consistent annual expansion, with the market crossing $39B in 2026 and $52B by 2030.
The investment case extends beyond sensor hardware. As biosensors scale, more healthcare data can be captured continuously outside traditional clinical settings. That increases the strategic value of the software, analytics, and care platforms capable of turning those signals into actionable clinical information.
For healthtech operators, this creates a different competitive question. Capturing another biomarker is useful, but integrating that data into clinical workflows and demonstrating that it changes decisions is potentially more valuable.
Why it matters: the biosensor market’s expansion could shift value toward companies sitting between devices and care delivery. Investors should watch for platforms that can aggregate sensor data, integrate it into provider workflows, and convert growing volumes of real time information into measurable clinical or operational outcomes. (More)
PRESENTED BY DYNAMO SOFTWARE
13 Questions. 3 Minutes. Your Firm's AI Readiness Score.
87% of GPs expect AI to reshape investment management within five years— yet most firms are still stuck at the pilot stage, unsure what's holding them back.”
The DynamoAI Readiness Assessment gives you a clear answer in under three minutes. Answer 13 questions and get a score across the four areas that decide real-world AI performance: Data Foundation, Tooling & Infrastructure, Team & Adoption, and Strategy & Urgency.
Each category is scored on its own, so you don't just get a number — you get a clear picture of where your firm is strong and where to focus first. It's complimentary, takes three minutes, and turns AI ambition into a concrete next step.
Take the free assessment and see where your firm stands today.
COMPLIANCE CORNER
Healthcare Compliance Is Becoming a Strategic Risk
Healthcare compliance is moving from a back-office function to a core operating and investment consideration. MRO’s latest analysis points to a more demanding environment: organizations must simultaneously enable faster access to health data, protect it from cyber threats, comply with evolving regulations and manage increasingly complex billing requirements.
The numbers illustrate the pressure. Governmental and commercial payment-integrity audits have risen nearly 58%, while HIPAA enforcement has generated more than $8M in financial penalties. Meanwhile, large healthcare data breaches affected 62 million people in 2025, and 86% of patients surveyed by MRO say they are concerned about their healthcare data being compromised.
For healthcare executives and investors, the implication is broader than regulatory exposure. Compliance infrastructure is becoming part of enterprise resilience. Organizations with stronger governance, audit readiness, secure data exchange and third-party controls should be better positioned to scale without accumulating regulatory liabilities.
Bottom line: in healthcare, compliance is increasingly less about avoiding penalties—and more about protecting the ability to operate, scale and earn trust.
COMPETITIVE LANDSCAPE SNAPSHOT
TREND TO WATCH
Biotech: Capital Is Coming Back — But It’s Becoming More Selective
Biotech is regaining access to capital, but the funding environment looks very different from the 2020–21 boom.
The chart shows biotech financing peaking at roughly $120B in 2020–21, before falling sharply. In 2025, funding recovered to nearly $70B, while Q1 2026 already reached around $30B. But the composition matters: follow-ons and other financing are doing more of the heavy lifting, while venture capital remains comparatively selective.
EY’s latest Beyond Borders report reinforces the shift. Capital is increasingly concentrating on later-stage companies, validated platforms and assets closer to commercialization, while investors remain cautious around earlier-stage risk. At the same time, M&A is becoming an increasingly important source of liquidity and strategic capital.
The takeaway for investors: biotech remains a structural growth story, but the next cycle will be defined less by capital availability and more by capital allocation. In this market, clinical validation, differentiated platforms and a credible path to commercialization matter more than ever.
INTERESTING ARTICLES
